Pancreatic adverse events in patients treated with immune checkpoint inhibitors

BACKGROUND AND AIM: The inhibition of cytotoxic T‐lymphocyte associated antigen‐4 (CTLA‐4) and programmed cell death‐1 (PD‐1) has been a target for multiple drugs to enhance the T‐cell antitumor activity. However, these immune checkpoint inhibitors (ICIs) come with a panel of immune‐related adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Hana, Caroline, Rehman, Tauseef, Park, Kyeeun, Carracedo Uribe, Carlos, Aung, Pyi Phyo, Hunis, Brian, Salzberg, Matthew, Zikria, Jennifer, Hussein, Atif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037034/
https://www.ncbi.nlm.nih.gov/pubmed/36968572
http://dx.doi.org/10.1002/jgh3.12875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037034/
https://www.ncbi.nlm.nih.gov/pubmed/36968572
http://dx.doi.org/10.1002/jgh3.12875

Ejemplares similares